Telix gets FDA alignment to expand prostate cancer trial to U.S.

July 1, 2026 9:31 PM

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) announced it has reached alignment with the U.S. Food and Drug Administration to advance ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found